Publications by authors named "Rodriguez-Serna M"
Article Synopsis
- A study was conducted on patients with atopic dermatitis (AD) to explore the impact of atopic comorbidities like asthma and allergic rhinitis on their treatment response.
- Data was collected from the BIOBADATOP registry, involving 509 patients, mostly adults with severe AD, and analyzed for associations between atopic comorbidities and clinical characteristics.
- Results indicated that patients with personal atopic comorbidities had more severe symptoms and a higher history of treatments, but no significant differences in treatment response were found after 6 and 12 months, suggesting a need for longer follow-up.
Background: Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.
Objectives: This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.
Article Synopsis
- Patch test outcomes can be affected by age, but there are mixed findings on how age impacts these results.
- The study involved over 13,000 patients and revealed that middle-aged adults (31-65 years) had the highest rates of positive skin sensitisation results, particularly for certain substances like nickel and potassium dichromate.
- Overall, while age does influence some patch test results, most allergens showed consistent reactivity across ages, underscoring the importance of standard testing regardless of age.
Article Synopsis
- Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are different inflammatory skin conditions, and the study aimed to explore their relationship further among patients referred for patch testing.
- Researchers analyzed data from the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy (REIDAC) to compare contact allergies and other clinical details between patients with AD and those without.
- The study found that while both groups showed similar allergy profiles, patients with AD had a lower likelihood of being sensitized to nickel sulphate compared to non-AD patients.
After the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish Standard Series patch testing. Hydroxyethyl methacrylate (2% pet.), textile dye mixt (6.
View Article and Find Full Text PDFAtypical bullae in hands and trunk: An unusual suspect.
Enferm Infecc Microbiol Clin (Engl Ed)
October 2024
Background: Psoriasis is a chronic inflammatory dermatosis whose clinical and topographic distribution requires differential diagnosis, or the possible association with allergic contact dermatitis (ACD), requiring patch testing (PT) as part of the diagnostic procedure.
Objectives: To describe the epidemiological, clinical, and allergic profile of patients with a primary or secondary diagnosis of psoriasis undergoing PT and compare them with patients with a diagnosis of ACD at the end of the diagnostic process.
Methods: Cross-sectional study with data from REIDAC from 2018 through 2023 of selected patients with a diagnosis of psoriasis and/or ACD.
Article Synopsis
- A multicentric study in Spain analyzed data from 10,176 patients over four years to explore polysensitization (PS), finding that 8.3% of participants were polysensitized.
- Factors associated with PS included older age, atopic dermatitis, and exposure at specific body locations, with significant differences in allergen relevance compared to those with fewer sensitivities.
- The research revealed distinct allergen clusters among polysensitized patients, suggesting that cross-reactivity and sensitization may contribute to these patterns.
Background: A global epidemic of allergic contact dermatitis to (meth)acrylates has been described in relation to the widespread use of manicure products.
Objectives: To evaluate the frequency of sensitization to 2-hydroxyethyl methacrylate (2-HEMA) among consecutively patch tested patients with eczema in Spain; the percentage of current relevance; the MOAHLFA index; and, the potential sources of exposure to (meth)acrylates.
Methods: From January 2019 to December 2022, 2-HEMA 2% pet.
Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown.
Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para-phenylenediamine (PPD) and specific disperse dyes.
Materials And Methods: We analysed all consecutive patients patch-tested with TDM from the Spanish Contact Dermatitis Registry (REIDAC), from 1 January 2019 to 31 December 2022.
Background: The epidemiological surveillance of contact dermatitis is one of the objectives of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy. Knowing whether the prevalence of positive tests to the different allergens changes over time is important for this monitoring process.
Objectives: To describe the various temporary trends in allergen positivity in the GEIDAC standard series from 2018 through December 31, 2022.
Background: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases.
View Article and Find Full Text PDFPersistent localized dermatitis (PLD) or eczema flare-ups (EF) may occur in atopic dermatitis (AD) patients treated with dupilumab. They may reflect concomitant allergic contact dermatitis (ACD) exposed by the inhibition of the Th2 pathway by dupilumab in some cases. To evaluate the prevalence and etiology of these events and the impact of dupilumab on patch test outcome.
View Article and Find Full Text PDFBackground: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential.
Materials And Method: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs).
Background: Current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known.
Objectives: To study the frequency of sensitization, risk factors and simultaneous sensitization between the four isothiazolinones.
Materials And Methods: We analysed all 2019-2021 consecutive patients patch-tested with MI (0.